Teva Pharmaceuticals has agreed to pay $420 million to settle shareholder litigation alleging the company concealed an anti-competitive scheme to fix the prices of about 50 generic drugs, according to court documents filed in the U.S. District Court for the District of Connecticut on Tuesday.